Trends in Pricing and Out-of-Pocket Spending on Entecavir Among Commercially Insured Patients, 2014-2018

Jonathan D Alpern; Heesoo Joo; Ben Link; Antonio Ciaccia; William M Stauffer; Nathan C Bahr; Thomas M Leventhal

doi:10.1001/jamanetworkopen.2021.44521

Trends in Pricing and Out-of-Pocket Spending on Entecavir Among Commercially Insured Patients, 2014-2018

JAMA Netw Open. 2022 Jan 4;5(1):e2144521. doi: 10.1001/jamanetworkopen.2021.44521.

Authors

Jonathan D Alpern¹, Heesoo Joo², Ben Link³, Antonio Ciaccia³, William M Stauffer^{2

4}, Nathan C Bahr⁵, Thomas M Leventhal⁶

Affiliations

¹ HealthPartners Infectious Diseases, St Paul, Minnesota.
² Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, Georgia.
³ 46brooklyn Research, Dayton, Ohio.
⁴ Center for Global Health and Social Responsibility, School of Public Health, University of Minnesota, Minneapolis.
⁵ Division of Infectious Diseases, Department of Medicine, University of Kansas Medical Center, Kansas City.
⁶ Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Minnesota, Minneapolis.

Abstract

This cross-sectional study of health claims from patients with private insurance examines trends in the cost of entecavir prescribed for chronic hepatitis B treatment.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Antiviral Agents / economics*
Deductibles and Coinsurance / trends
Fees and Charges / trends*
Financing, Personal / trends*
Guanine / analogs & derivatives*
Guanine / economics
Health Expenditures / trends*
Humans
United States

Substances

Antiviral Agents
entecavir
Guanine

Grants and funding

K23 NS110470/NS/NINDS NIH HHS/United States